Regulation of autoantibodies in inflammatory demyelinating polyneuropathy: spontaneous and therapeutic.
We have analyzed the role and regulation of autoantibodies in inflammatory demyelinating polyneuropathy (GBS/CIDP). The clinical significance of pathogenic autoantibodies to peripheral nerve tissue is suggested by the beneficial response of many of these patients to plasmapheresis and treatment with high doses of polyspecific IVIgG. Recovery, whether spontaneous or therapeutically-induced, is associated with anti-idiotypic suppression of the antoantibodies. Preliminary results suggest that these autoantibodies share cross-reactive idiotypes or, alternatively, that the regulatory anti-idiotypic antibodies are multireactive.
Lundkvist
I
I
Department of Immunohematology and Bloodbank, University Hospital, Leiden, The Netherlands.
van Doorn
P A
PA
Vermeulen
M
M
van Lint
M
M
van Rood
J J
JJ
Brand
A
A
D001323:Autoantibodies / Q000276:immunology*; D003429:Cross Reactions; D003711:Demyelinating Diseases / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007167:Immunotherapy; D011129:Polyradiculoneuropathy / Q000276:immunology* / Q000628:therapy
D001323:Autoantibodies; D007074:Immunoglobulin G; D007130:Immunoglobulin Idiotypes